Home
1
News
2
最新消息
3
[2025/06] Exhibition announcement- LTX-568 draws global attention at the 2025 BIO International Convention4
https://www.lyntonix.com/en/ LYNTONIX, INC.
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan
According to Article 3, Paragraph 1 of “Regulations Governing the Identification of High-Risk Innovative Startups as Referred to in Article 12 of the Income Basic Tax Act”, LYNTONIX has been approved as a “High-Risk Innovative Startup”. Investments in LYNTONIX are therefore eligible for the Income Basic Tax credit. https://www.lyntonix.com/en/hot_522358.html [2025/03] News- LYNTONIX has been approved as a High-Risk Innovative Starup by Industrial Development Administration (IDA), Ministry of Economic Affairs (MOEA), Taiwan 2025-09-05 2026-09-05
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan https://www.lyntonix.com/en/hot_522358.html
LYNTONIX, INC. 17, Xuzhou Road, Room 936, Taipei, 100 Taiwan https://www.lyntonix.com/en/hot_522358.html
https://schema.org/EventMovedOnline https://schema.org/OfflineEventAttendanceMode
2025-09-05 http://schema.org/InStock TWD 0 https://www.lyntonix.com/en/hot_522358.html

LYNTONIX was honored to be one of the Taiwanese biomedical startup companies selected by NSTC to participate in 2025 US BIO, promoting our innovatice product, LTX-568. During the convention, LTX-568 attracted strong interest and received highly positive feedback from industry experts and global partners. We look forward to advancing LTX-568 into clinical studies, and conquering the unmet needs for IBS abdominal pain.






Previous Back to List Next